Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 3, May-June, p. 455–461

Publication type: original article

Language: English

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Ugur Keklikci1,A,B,C,D,E,F, Birgul Dursun1,B,C, Abdullah Kursat Cingu1,C,D

1 Department of Ophthalmology, Dicle University Faculty of Medicine, Diyarbakir, Turkey


Background. Vernal keratoconjunctivitis (VKC) is a chronic, bilateral inflammation of the conjunctiva that mostly affects children and young adult males. Management of VKC is primarily aimed at reducing symptoms and preventing serious vision threatening sequelae.
Objectives. To assess the efficacy of topical cyclosporine A (CsA) 0.05% on the signs and symtomps in the management of VKC.
Material and Methods. This is a placebo-controlled, randomized prospective study. Sixty-two patients with VKC were included in this study. Patients were randomly assigned (1 : 1) to treatment with topical 0.05% CsA eyedrops or a placebo (artificial tears) for a period of 4 weeks, 4 times daily. Ocular signs and symptoms were in all patients scored at entry and at the end of 4 weeks.
Results. When pre-treatment mean signs and symptoms scores were compared in both groups, there was no significant difference (p > 0.05). However, mean post-treatment scores as regards signs and symptoms were found to be lower in cyclosporine group than those in placebo group (p < 0.001). No side effects of the treatment with CsA 0.05% eyedrops were observed.
Conclusion. It was found that topical CsA 0.05% eyedrops were safe and effective in the treatment of patients with VKC.

Key words

cyclosporine, sign, symptom, topical, vernal keratoconjunctivitis.

References (45)

  1. Bonini S, Coassin M, Aronni S, Lambiase A: Vernal keratoconjunctivitis. Eye 2004, 18, 345–351.
  2. Spadavecchia L, Fanelli P, Tesse R, Brunetti L, Cardinale F, Bellizzi M, Rizzo G, Procoli U, Bellizzi G, Armenio L: Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol 2006, 17, 527–532.
  3. Mantelli F, Santos MS, Petitti T, Sgrulletta R, Cortes M, Lambiase A, Bonini S: Systematic review and metaanalysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis. Br J Ophthalmol 2007, 91, 1656–1661.
  4. Emre S, Başer E, Oztürk B, Zorlu S, Uzun O, Gülhan C: Corneal biochemical features of patients with vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 2013, 251, 555–558.
  5. Sangwan VS, Jain V, Vemuganti GK, Murthy SI: Vernal keratoconjunctivitis with limbal stem cell deficiency. Cornea 2011, 30, 491–496.
  6. Le Q, Wang Y, Xu J: In vivo confocal microscopy of long-standing mixed-form vernal keratoconjunctivitis. Ocul Immunol Inflamm 2010, 18, 349–351.
  7. Leonardi A, Busca F, Motterle L, Cavarzeran F, Fregona IA, Plebani M, Secchi AG: Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study. Acta Ophthalmol Scand 2006, 84, 406–410.
  8. Keklikci U, Soker SI, Soker Cakmak S, Ozkul S, Sakalar YB, Unlu K: Unilateral vernal keratoconjunctivitis: A case report. Eur J Ophthalmol 2007, 17, 973–975.
  9. Pucci N, Massai C, Bernardini R, Caputo R, Mori F, De Libero C, Novembre E, De Martino M, Vierucci A: Eyelash length in children with vernal keratoconjunctivitis: effect of treatment with cyclosporine eye drops. Int J Immunopathol Pharmacol 2007, 20, 595–599.
  10. Bozkurt B, Artac H, Arslan N, Gokturk B, Bozkurt MK, Reisli I, Irkec M: Systemic atopy and immunoglobulin deficiency in Turkish patients with vernal keratoconjunctivitis. Ocul Immunol Inflamm 2013, 21, 28–33.
  11. Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N, Kosrirukvongs P, Saengin P, Vichyanond P: A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol 2012, 30, 177–184.
  12. Nussenblatt RB, Palestine AG: Cyclosporine A: immunology, pharmacology and therapeutic uses. Surv Ophthalmol 1986, 31, 159–169.
  13. Borel JF, Baumann G, Chapman I, Donatsch P, Fahr A, Mueller EA, Vigouret JM: In vivo pharmacological effects of cyclosporin and some analogues. Adv Pharmacol 1996, 35, 115–246.
  14. Whitcup SM, Chan CC, Luyo DA, Bo P, Li Q: Topical cyclosporine inhibits mast cell-mediated conjunctivitis. Invest Ophthalmol Vis Sci 1996, 37, 2686–2693.
  15. Daniell M, Constantinou M, Vu HT, Taylor HR: Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol 2006, 90, 461–464.
  16. Bonini S, Bonini S, Lambiase A, Marchi S, Pasqualetti P, Zuccaro O, Rama P, Magrini L, Juhas T, Bucci MG: Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology 2000, 107, 1157–1163.
  17. De Smedt S, Nkurikiye J, Fonteyne Y, Tuft S, De Bacquer D, Gilbert C, Kestelyn P: Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial. Br J Ophthalmol 2012, 96, 323–328.
  18. Ang M, Ti SE, Loh R, Farzavandi S, Zhang R, Tan D, Chan C: Steroid-induced ocular hypertension in Asian children with severe vernal keratoconjunctivitis. Clin Ophthalmol 2012, 6, 1253–1258.
  19. Oner V, Türkcü FM, Taş M, Alakuş MF, Işcan Y: Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety. Jpn J Ophthalmol 2012, 56, 312–318.
  20. Tabbara KF: Ocular complications of vernal keratoconjunctivitis. Can J Ophthalmol 1999, 34, 88–92.
  21. Leonardi A: Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res 2002, 21, 319–339.
  22. Akpek EK, Dart JK, Watson S, Christen W, Dursun D, Yoo S, O’Brien TP, Schein OD, Gottsch JD: A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 2004, 111, 476–482.
  23. Bonini S, Sacchetti M, Mantelli F, Lambiase A: Clinical grading of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol 2007, 7, 436–441.
  24. Dada T, Konkal V, Tandon R, Singh R, Sihota R: Corneal topographic response to intraocular pressure reduction in patients with vernal keratoconjunctivitis and steroid-induced glaucoma. Eye 2007, 21, 158–163.
  25. Verin P, Allewaert R, Joyaux JC, Piozzi E, Koliopoulos J, Bloch-Michel E: Lodoxamide Study Group Comparison of lodoxamide 0.1% ophthalmic solution and levocabastine 0.05% ophthalmic suspension in vernal keratoconjunctivitis. Eur J Ophthalmol 2001, 11, 120–125.
  26. Abelson MB: A review of olopatadine for the treatment of ocular allergy. Expert Opin Pharmacother 2004, 5, 1979–1994.
  27. Turan-Vural E, Acar BT, Acar S: The efficacy of topical interferon alpha 2b treatment in refractory vernal keratoconjunctivitis. Ocul Immunol Inflamm 2012, 20, 125–129.
  28. Avunduk AM, Avunduk MC, Erdol H, Kapicioglu Z, Akyol N: Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis. Ophthalmologica 2001, 215, 290–293.
  29. Bielory L, Bonini S, Bonini S: Allergic eye disorders. Clin Allergy Immunol 2002, 16, 311–323.
  30. Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R, Campa L, Vierucci A: Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 2002, 89, 298–303.
  31. Keklikci U, Soker SI, Sakalar YB, Unlu K, Ozekinci S, Tunik S: Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children. Jpn J Ophthalmol 2008, 52, 357–362.
  32. Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N, Kosrirukvongs P, Saengin P, Vichyanond P: A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol 2012, 30, 177–184.
  33. Tesse R, Spadavecchia L, Fanelli P, Rizzo G, Procoli U, Brunetti L, Cardinale F, Miniello VL, Bellizzi M, Armenio L: Treatment of severe vernal keratoconjunctivitis with 1% topical cyclosporine in an Italian cohort of 197 children. Pediatr Allergy Immunol 2010, 21, 330–335.
  34. Hunter PA, Wilhelmus KR, Rice NS, Jones BR: Cyclosporin A applied topically to the recipient eye inhibits corneal graft rejection. Clin Exp Immunol 1981, 45, 173–177.
  35. Kana JS, Hoffmann F, Buchen R, Krolik A, Wiederholt M: Rabbit corneal allograft survival following topical administration of cyclosporin A. Invest Ophthalmol Vis Sci 1982, 22, 686–690.
  36. Zierhut M, Thiel HJ, Weidle EG, Waetjen R, Pleyer U: Topical treatment of severe corneal ulcers with cyclosporin A. Graefes Arch Clin Exp Ophthalmol 1989, 227, 30–35.
  37. Gunduz K, Ozdemir O: Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res 1997, 29, 405–408.
  38. Sall K, Stevenson OD, Mundorf TK, Reis BL: Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000, 107, 631–639.
  39. Hingorani M, Moodaley L, Calder VL, Buckley RJ, Lightman S: A randomized, placebocontrolled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology 1998, 105, 1715–1720.
  40. BenEzra D, Pe’er J, Brodsky M, Cohen E: Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis.Am J Ophthalmol 1986, 101, 278–282.
  41. Bleik JH, Tabbara KF: Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991, 98, 1679–1684.
  42. Gupta V, Sahu PK: Topical cyclosporin A in the management of vernal keratoconjunctivitis. Eye 2001, 15, 39–41.
  43. Ozcan AA, Ersoz TR, Dulger E: Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops. Cornea 2007, 26, 1035–1038.
  44. Lambiase A, Leonardi A, Sacchetti M, Deligianni V, Sposato S, Bonini S: Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitisin a randomized, double-masked, controlled 2-year study. J Allergy Clin Immunol 2011, 128, 896–897.
  45. Pucci N, Caputo R, Mori F, De Libero C, Di Grande L, Massai C, Bernardini R, Novembre E: Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis. Int J Immunopathol Pharmacol 2010, 23, 865–871.